Compass Therapeutics Inc. has announced a new drug candidate, CTX-10726, a novel tetravalent PD-1 x VEGF-A bispecific antibody.

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and ...

Naya Biosciences Inc. has expanded its bifunctional antibody pipeline to include NY-500, a novel PD-1 x VEGF tetravalent bifunctional antibody for the treatment of hepatocellular carcinoma (HCC) and ...

Stifel Nicolaus analyst Stephen Willey has maintained their bullish stance on CMPX stock, giving a Buy rating today.Stay Ahead of the ...

The dengue vaccine market is on track for robust growth, with increasing global awareness, governmental support, and ...

Top-line Phase 2/3 data readout for CTX-009, now named tovecimig (a DLL4 x VEGF-A bispecific), in patients with biliary tract cancer (BTC) is on ...

PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications ...

After hours: January 10 at 4:01:12 PM EST Loading Chart for MGNX ...

To schedule a 1on1 investor meeting with Valneva, institutional investors and analysts can contact Valneva’s investor relations department at [email protected].